Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2
Sienna Biopharmaceuticals Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
QIMC Further Derisks Nova Scotia Natural Hydrogen Multi-Gas System with New Thermogenic Gas and Helium Results
Flow Metals Secures Little Gold Creek Headwaters, Completing Strategic Consolidation of Sixtymile Gold District
Highlights Include Iron Values Exceeding 30%, Nickel up to 500 ppm, Cobalt up to 187 ppm and Vanadium up to 1,710 ppm
